This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Debate over Hepatitis C drug pricing and access
A Senate Finance Committee report criticizes Gilead Sciences for pricing Sovaldi and Harvoni at high levels to maximize revenue, limiting patient access and driving up government program costs. The study notes over 600,000 treated worldwide and warns of similar trends with future therapies.
MENTIONED IN THIS ARTICLE
Washington
Senate
Senate Finance Committee
Gilead Sciences
Ron Wyden
Oregon
Gilead
Sovaldi
Harvoni
Wyden
Chuck Grassky
Lowa
Sovald
U.S
Medicare
Grassley
Finance Committee
Pharmaceutical
Tobosa Developmental Services
Jo E H. Madrid
Joe
Scot Tobosa
Tobosa
Tobosa Development and Training Center
TDTC
Roswell
ENMU
Western Michigan University
Artesio High
Lowe
Indiana
Madrid
Actios
Linda
Valerie
Kelly
Donicio